I wrote a Greasemonkey script to deal with Yahoo's poorly implemented ignore feature. It will de-clutter the messageboard by removing all of your ignored users from any sort of visibility. Just google "Yahoo Finance Messageboards Total Ignore" (with the quotes) and you will see a link to userscripts-mirrorDOTorg.
Lots of bad news ahead....first the cc and mounting losses...then the secondary...and a continuation of poor belviq sales...it just never ends??? dyodd
...if you bothered to calculated your credibility factor you might notice that you have been 100% wrong for years...LOL...LOL..WHAT A CORRUPT SCAM ARTIST...DYODD
So why do they keep bashing here? Kinda seems obvious, doesn't it?
THEY ARE HERE TO DAMAGE THE SHARE PRICE WITH LIES AND DISTORTIONS. PERIOD.
Sentiment: Strong Buy
Yes. Right you are Sharon. Thought we were just talking about B supply revenue. They won't amortize either the milestone or the B revenue as Jim has conjectured above.
In the studies that will look at the efficacy of APD371, is that 371 does not need to be better to other pain medications, it just needs to be equal in efficacy with low side effects and tolerability (which the phase 1a study indicates it will be) in my opinion. The other interesting thing about the efficacy studies is how will efficacy be measured. In my several hospital stays, they do the old "what is your pain level" question on a scale of 1 to 5 (maybe 1 to 10). As far as I know there is no lab test that would indicate a pain level?
If someone has actual experience in drug study design you can correct me if I'm wrong, but it seems like no placebo arm would be used in this pain medication study with patients experiencing pain but that the comparable arms would be standard pain medications both opoid and non-opoid medications.
I do think if the phase 2a and/or 2b studies show good efficacy results, Arena should apply for "fast track" and "innovative drug" status with the FDA. Spark Therapeutics (ONCE) which is one of the other stocks I own has gotten these status' with the FDA for one of it's phase 3 drugs.
Forgot about the milestone payment and it depends on whether Arena amortizes it or not. My guess because of the amount they don't amortize.
No, No typo. in addition to the 1.4M in revenue there is a 3 Million milestone payment that ARNA will book 1Q.
I just voted NO as well and likely may not do any good. I came into this in 2010 believing in the management team, and am thankful to them for getting B to FDA approval. Beyond that there are almost 3 years now of constant and deepening erosion of what is most valuable to us all if all are honest and that is the share price.
The science can not win out alone. Jack and team have failed to build any real communicational bridges and alliances where they are seriously needed on wall street and media. There are many things broken right now and I only bring up one area that is busted beyond belief as no PR/news other than a major partnership or BO will provide any gains that can hold for more than a few hours to a day - unless purposely pumped and driven to dilution like in January. No one with credibility in this industry supports Arena and Arena has not tried to remedy this problem so until this team can fix that one area, all news we get will just sell off quickly into inferno red - proof is in the APD371 news this last week. There were no supporting articles to keep momentum moving Jack, you and your team are either too lazy or you have a far different agenda than we need.
Thanks for starting the thread fugs.
bashers are sodomists.
Sentiment: Strong Buy
It would be a trifecta. Again, very creative thinking but something that is not improbable at all. I think we will see alliances like you have wrote about happen in the coming years. What you are writing about would really increase the consumer awareness of belviq which imo is the key issue now. Belviq works and a much better/stronger marketing approach like you have outlined would make it a BB.